Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Underdosed NOACs in very elderly atrial fibrillation patients
ChiCTR2300076161Phase 4Not yet recruiting
- Sponsor
- Beijing Hospital
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of rivaroxaban in Atrial fibrillation (AFib) (2 arms), sponsored by Beijing Hospital. Primary endpoints: all-cause mortality, massive haemorrhage and 2 more. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
rivaroxaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on ChiCTR2300076161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076161.